Royce & Associates LP Cytom X Therapeutics, Inc. Transaction History

Royce & Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$18.04 - $26.41 $9,001 - $13,178	-499 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$21.38 - $29.68 $5,858 - $8,132	274 Added 121.78%	499 $11,000
Q1 2018 May 14, 2018	SELL	$21.76 - $34.22 $3,068 - $4,825	-141 Reduced 38.52%	225 $6,000
Q4 2017 Feb 09, 2018	SELL	$19.0 - $23.09 $1,425 - $1,731	-75 Reduced 17.01%	366 $8,000
Q3 2017 Nov 13, 2017	BUY	$13.53 - $18.17 $5,966 - $8,012	441	441 $8,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $70.6M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.